Arcadia Biosciences Reports Q2 Loss of $4.5 Million, Revenue of $1.5 Million.
PorAinvest
viernes, 15 de agosto de 2025, 5:12 am ET1 min de lectura
RKDA--
Arcadia's adjusted earnings per share (EPS) were 2 cents for the quarter, down from 16 cents in Q2 2024. The company's gross margins have consistently exceeded 30% for ten consecutive quarters, indicating strong operational efficiency. However, total operating expenses rose dramatically by 390% in Q2 2025, suggesting escalating costs could impact future profitability [1].
Arcadia also announced the receipt of 2.7 million shares of stock in Above Food Ingredients Inc. as partial repayment related to a previous sale. This, along with the elimination of $1 million in contingent liabilities, brings the total eliminated to $2 million year-to-date [1]. The company continues to pursue the repayment of the remaining outstanding balance of the note receivable related to the sale of GoodWheat™ assets.
Arcadia's pending business combination with Roosevelt Resources continues to move forward. The company recently filed an amendment to the initial Form S-4 registration statement to provide responses to comments received from the SEC and to provide updated financial information through the first quarter of 2025 for both Arcadia Biosciences and Roosevelt Resources [1].
References:
[1] https://www.quiverquant.com/news/Arcadia+Biosciences+Reports+11%25+Revenue+Growth+Driven+by+24%25+Increase+in+Zola%C2%AE+Sales+and+Reduces+Liabilities+by+%241+Million
Arcadia Biosciences reported a Q2 loss of $4.5 million, or $3.26 per share, and revenue of $1.5 million. The agricultural biotechnology trait company's adjusted earnings per share were 2 cents.
Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, reported its financial results for the second quarter and first half of 2025. The company experienced an 11% increase in total revenues year over year, driven by a significant 24% growth in Zola® coconut water sales. Despite this revenue growth, Arcadia reported a net loss of $4.5 million for the second quarter, an increase from the net income of $1.1 million in Q2 2024 [1].Arcadia's adjusted earnings per share (EPS) were 2 cents for the quarter, down from 16 cents in Q2 2024. The company's gross margins have consistently exceeded 30% for ten consecutive quarters, indicating strong operational efficiency. However, total operating expenses rose dramatically by 390% in Q2 2025, suggesting escalating costs could impact future profitability [1].
Arcadia also announced the receipt of 2.7 million shares of stock in Above Food Ingredients Inc. as partial repayment related to a previous sale. This, along with the elimination of $1 million in contingent liabilities, brings the total eliminated to $2 million year-to-date [1]. The company continues to pursue the repayment of the remaining outstanding balance of the note receivable related to the sale of GoodWheat™ assets.
Arcadia's pending business combination with Roosevelt Resources continues to move forward. The company recently filed an amendment to the initial Form S-4 registration statement to provide responses to comments received from the SEC and to provide updated financial information through the first quarter of 2025 for both Arcadia Biosciences and Roosevelt Resources [1].
References:
[1] https://www.quiverquant.com/news/Arcadia+Biosciences+Reports+11%25+Revenue+Growth+Driven+by+24%25+Increase+in+Zola%C2%AE+Sales+and+Reduces+Liabilities+by+%241+Million

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios